Hyderabad, India & Tokyo, Japan June 07, 2016
xcelra, Asia’s leading Knowledge Solutions Company today announced that it has entered into a strategic Drug Repurposing collaboration with Tokyo-based pharmaceutical company, Astellas Pharma Inc. The collaboration is focused on identifying novel therapeutic indications for a number of undisclosed Astellas’ shelved pharma assets.
Astellas will have access to Excelra’s proprietary Drug Repurposing Platform (GRIP), which is a combination of proprietary Repurposing Database, Repurposing Algorithms, Analytics tools and Visualization engine. The collaboration offers a unique proposition to combine technology with scientific expertise in deciphering novel Mechanism of Actions using drug-disease-target relationships, to identify alternative indications for existing assets.
About Excelra Knowledge Solutions Pvt Ltd.:
Excelra Knowledge Solutions is a leading Informatics Solutions company that leverages its extensive scientific knowledge base, technology and relevant domain expertise to provide intelligent data and analytics solutions to customers globally. Excelra’s expertise span across Data Solutions, Data Indexing & Abstraction and Data Analytics. The company has over nine successful Drug Repurposing collaborations with leading pharmaceutical companies and has developed a proprietary Drug Repurposing Platform and Computational Biology capabilities.
Excelra has a team of 650+ scientists with rich experience in Chemistry, Biology and Clinical Sciences who are engaged in curation of databases spanning SAR (GOSTAR), Biomarkers (GOBIOM) and Clinical outcomes. Excelra’s portfolio of customers include some of the world’s largest Pharmaceutical, Biotechnology, Publishing, Agrochemical, Life Sciences and Academic institutions in the USA, EU, Japan and Asia Pacific. For more information please visit www.excelra.com
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.